Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Mou
Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort study
Abstract The prognostic significance of event-free survival at 24 months (EFS24) in mantle cell lymphoma (MCL) has not been fully defined in the era of contemporary immunochemotherapy. We analyzed 3179 patients from five cohorts (Mayo Clinic/Iowa MER, US 12-center, BC Cancer, Swedish, and Danish) diagnosed between 2002 and 2020. Two treatment eras were defined per cohort based on shifts in frontline immunochemotherapy.
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study
|
Abstract Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L).
By Jean L. Koff, Melissa Larson, Jonathon Cohen, Izidore S. Lossos, Peter Martin, Thomas M Habermann, Carla Casulo, Samuel Yamshon, Andrea Lo-Rossi, Connie Lee Batlevi, Anthony Masaquel, Yong Mun, Yucai Wang, Arushi Khurana, Grzegorz Nowakowski, Dai Chihara, Eric Mou, Umar Farooq, Dilan A. Patel, Amy Ayers, James R. Cerhan, Christopher Flowers, Matthew J. Maurer, Loretta J Nastoupil, Ashwini Shewade, Tanner W. Reicks
|
Nature
Verified
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy
|
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic, Anita Kumar
|
Nature
Verified
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts - Blood Cancer Journal
|
Abstract Follicular lymphoma (FL) 3B is considered an aggressive lymphoma, however recent studies have challenged this paradigm. Additional controversy involves the clinical implication of pure FL3B (FL3Bp) vs FL3B with concurrent diffuse large B cell lymphoma (DLBCL) (FL3Bc). To address these questions, we performed a pooled study of the MER and LEO cohorts comparing 464 newly diagnosed, R-CHOP-treated patients with FL1-2 (n = 216), FL3A (n = 170), FL3B (n = 78) and 739 DLBCL.
By Patrizia Mondello, Brianna J. Negaard, Andrew Feldman, Dai Chihara, Jason Romancik, Eric Mou, Yucai Wang, Rebecca King, Anne Novak, Thomas M Habermann, Brad S. Kahl, Grzegorz Nowakowski, Loretta J Nastoupil, James R. Cerhan, Christopher Flowers, Izidore S. Lossos, Richard Burack, Matthew J. Maurer
|
Nature
Verified
Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T‐cell lymphomas
To the Editor: Cytotoxic cutaneous T-cell lymphomas (CCTCLs) are uncommon neoplasms involving skin-tropic T cells expressing cytotoxic markers (e.g. TIA-1, granzyme, and/or perforin).
The Power of Trust
On a warm and sunny Saturday morning in Northern California, I drove across the bay to attend a community support group for patients living with neuroendocrine tumors (NETs). As a first-year oncology fellow, I would have an opportunity to speak with patients outside of the clinic setting, to better understand their lived experiences with an uncommon cancer.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack